Login to Your Account



As U.S. pays global tab on drug innovation, golden age could be wearing thin

By Mari Serebrov
Regulatory Editor

Tuesday, December 12, 2017

Are drug prices turning what's being called the golden age of science into the gilded age in the U.S.? That's the question Sen. Tim Kaine (D-Va.) posed Tuesday as the Senate Health, Education, Labor and Pensions Committee held its third hearing on high drug prices.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription